[HTML][HTML] Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …
Background Paclitaxel is currently only available as an intravenous (iv) formulation. DHP107
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …
Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - Annals of …, 2018 - yonsei.elsevierpure.com
Background: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim, JW Kim… - Annals of …, 2018 - pure.korea.ac.kr
Background: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - ANNALS OF …, 2018 - scholarworks.bwise.kr
Background: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim, JW Kim, SH Cho… - repository.ajou.ac.kr
BACKGROUND: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - Annals of oncology …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Paclitaxel is currently only available as an intravenous (iv) formulation. DHP107
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …
[引用][C] Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …
YK Kang, MH Ryu, SH Park, JG Kim, JW Kim… - Annals of …, 2018 - cir.nii.ac.jp
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus
iv paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy …
iv paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy …
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - ANNALS OF …, 2018 - scholar.korea.ac.kr
Background: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - Annals of …, 2018 - snucm.elsevierpure.com
Background: Paclitaxel is currently only available as an intravenous (iv) formulation.
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 …
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure of first …
YK Kang, MH Ryu, SH Park, JG Kim… - Annals of …, 2018 - annalsofoncology.org
Background Paclitaxel is currently only available as an intravenous (iv) formulation. DHP107
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …
is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated …